CONFIDENTIAL TREATMENT REQUESTED
BACE RESEARCH COLLABORATION AND LICENSE AGREEMENT
examination, oppositions, appeals and interference proceedings of Vitae Patents and/or Joint Patents, which are unnecessarily caused by Vitaes actions.
13.2.4 BIs Step-In Rights. BI shall have the right, but not the obligation, to assume responsibility for any Vitae Patent or Joint Patent which Vitae intends to abandon or otherwise cause or allow to be forfeited. Vitae shall give BI notice of its intent to abandon a Vitae Patent or Joint Patent in a particular country or jurisdiction within a reasonable period prior to a possible loss of rights, and BI shall thereafter have the right through Patent Counsel, at BIs sole expense, to prepare, file, prosecute and maintain such Vitae Patents or Joint Patents in such country or jurisdiction.
13.2.5 Vitaes Step-In Rights. Vitae shall have the right, but not the obligation, to assume responsibility for any BI Patents filed after the Effective Date that BI intends to abandon or otherwise cause or allow to be forfeited. BI shall give Vitae notice of its intent to abandon any Patents assigned to BI pursuant to Section 13.1.2 in a particular country or jurisdiction within a reasonable period prior to a possible loss of rights, and Vitae shall thereafter have the right through Patent Counsel, at Vitaes sole expense, to prepare, file, prosecute and maintain such BI Patents and/or Patents assigned to BI pursuant to Section 13.1.2 in such country or jurisdiction. Notwithstanding the above, in the event that BI elects not to file, prosecute or maintain a BI Patent or Joint Patent or claims in a BI Patent or Joint Patent that would affect the royalty owed Vitae under this Agreement, BI will reimburse Vitae for all out-of-pocket expenses incurred by Vitae in connection with Vitaes continued prosecution and maintenance of such Patent.
13.2.6 Execution of Documents by Agents. Each of the Parties shall execute, or have executed by its appropriate agents, such documents as may be necessary to obtain, perfect or maintain any Patent rights filed or to be filed pursuant to this Agreement, and shall cooperate with the other Party so far as reasonably necessary with respect to furnishing all information and data in its possession reasonably necessary to obtain or maintain such Patent rights.
13.2.7 Patent Term Extensions. BI shall have the right but not the obligation to seek extensions of the terms of any Vitae Patents, Joint Patents, BI Patents, BI Product Development Patents and Patents assigned to BI pursuant to Section 13.1.2 Covering a Product. At BIs request, Vitae either shall authorize BI to act as Vitaes agent for the purpose of making any application for any extensions of the term of such Patents or shall diligently seek to obtain and maintain such extensions, in either event, at BIs sole expense. BI shall consult with Vitae prior to its decision to seek a Patent term extension with respect to Vitae Patents, Joint Patents, BI Patents and Patents assigned to BI pursuant to Section 13.1.2, provided, however, that when the Parties hereto cannot reach an agreement for these Patents, BI shall have the right to determine which Vitae Patents, BI Patents, Joint Patents, or BI Product Development Patents to apply for Patent term extension in the Territory. In countries where more than one Patent term extension per Patent owner and per registered Product can be applied for, each Party shall have the right to request Patent term extension. For countries where only one registered Product per Patent can be extended, BI shall have final decision-making authority as to which Product the extension is applied. BI shall be responsible for listing to the Approved Drug Products with Therapeutic Equivalence Evaluation (known as the Orange Book) in case of United States,